Blue Jay Capital Management’s Integra LifeSciences IART Stock Holding History

Blue Jay Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-360,000	Closed	-$12.1M	–	18
2016 Q1	$12.1M	Buy	+360,000	New	+$11.2M	7.75%	5

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Blue Jay Capital Management's IART Position: Q2 2016 in Review

Blue Jay Capital Management sold out of Integra LifeSciences (IART) in Q2 2016, closing a stake of 360,000 shares — an estimated $12.1M sold.

Blue Jay Capital Management first reported a position in IART in Q1 2016 and held it in 1 quarter. The position peaked at $12.1M in Q1 2016. 210 funds tracked by Wall St. Rank hold IART as of Q2 2016.

Blue Jay Capital Management reported no remaining Integra LifeSciences position as of Q2 2016 after selling out during the quarter.
Blue Jay Capital Management sold 360,000 Integra LifeSciences shares in Q2 2016, an estimated $12.1M.
Blue Jay Capital Management first reported a position in Integra LifeSciences in Q1 2016 and held it in 1 quarter.
Blue Jay Capital Management's Integra LifeSciences position peaked at $12.1M in Q1 2016.
210 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2016.

Based on Blue Jay Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.